PT - JOURNAL ARTICLE AU - James S.H. Wong AU - Mohammadali Nikoo AU - Jean N. Westenberg AU - Janet G. Suen AU - Jennifer Wong AU - Reinhard M. Krausz AU - Christian G. Schütz AU - Marc Vogel AU - Jesse A. Sidhu AU - Jessica Moe AU - Shane Arishenkoff AU - Donald Griesdale AU - Nickie Mathew AU - Pouya Azar TI - Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: Protocol for an open-label, parallel-group, superiority, randomized controlled trial AID - 10.1101/2020.05.22.20106062 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.22.20106062 4099 - http://medrxiv.org/content/early/2020/05/26/2020.05.22.20106062.short 4100 - http://medrxiv.org/content/early/2020/05/26/2020.05.22.20106062.full AB - Background Buprenorphine/naloxone (Suboxone) is a current first-line treatment for opioid use disorder (OUD). The standard induction method of buprenorphine/naloxone requires patients to be abstinent from opioids and therefore experience withdrawal symptoms prior to induction, which can be a barrier in starting treatment. Rapid micro-induction (micro-dosing) involves the administration of small, frequent does of buprenorphine/naloxone and removes the need for a period of withdrawal prior to the start of treatment. This study aims to compare the effectiveness and safety of rapid micro-induction versus standard induction of buprenorphine/naloxone in patients with OUD.Methods This is a randomized, open-label, two-arm, superiority, controlled trial comparing the safety and effectiveness of rapid micro-induction versus standard induction of buprenorphine/naloxone for the treatment of OUD. A total of 50 participants with OUD will be randomized at one Canadian hospital. The primary outcome is successful induction of buprenorphine/naloxone with low levels of withdrawal. Secondary outcomes are treatment retention, illicit drug use, self-reported drug use behaviour, craving, pain, physical health, safety, and client satisfaction.Discussion This is the first randomized controlled trial to compare the effectiveness and safety of rapid micro-induction versus standard induction of buprenorphine/naloxone. This study will thereby generate evidence for a novel induction method which eliminates substantial barriers to the use of buprenorphine/naloxone in the midst of the ongoing opioid crisis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04234191Funding StatementThis work was supported by the Vancouver General Hospital & UBC Hospital Foundation. MN is supported by Frederick Banting and Charles Best Canada Graduate Scholarships (Funding Reference Number = 157934).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has received approval from the Research Ethics Board of the University of British Columbia (H19-03254).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable.